Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087685 · ClinicalTrials.gov registry record · Phase 2
RAD001 in Recurrent Endometrial Cancer Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00087685: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00087685 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087685, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if RAD001 can shrink or slow the growth of tumors in patients who have recurrent endometrial cancer. The safety of this drug will also be studied. Objectives: Primary Objective: 1\. To determine the efficacy of RAD001 in patients with progressive or recurrent endometrial cancer. Secondary Objective: 1. To determine the nature and degree of toxicity of RAD001 in this cohort of patients. 2. To characterize, in pre- and post- treatment tumor samples, when available, expression levels of total and phosphorylated mTOR (mammalian "target of rapamycin") as well as relevant upstream and downstream signaling components (optional).
Interventions
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2004-06 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087685
The ClinicalTrials.gov registry entry for NCT00087685 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 is the first listed.
NCT00087685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087685 about?
NCT00087685 is a clinical study titled "RAD001 in Recurrent Endometrial Cancer Patients". The goal of this clinical research study is to learn if RAD001 can shrink or slow the growth of tumors in patients who have recurrent endometrial cancer. The safety of this drug will also be studied. Objectives: Primary Objective: 1\. To determine the efficacy of RAD001 in patients with progressi...
What is the current status of trial NCT00087685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2004-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00087685?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00087685?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.